SCHEMBL4722044

SCHEMBL4722044

COC(=O)c1cc(C=O)ccc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.53
MEN1 O00255 5/20 0.50
KMT2A Q03164 5/20 0.50
LMNA P02545 4/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
MAPT P10636 4/20 0.48
HTT P42858 2/20 0.48
NPSR1 Q6W5P4 2/20 0.48
TSHR P16473 2/20 0.48
PTGS2 P35354 1/20 0.46
HPGD P15428 4/20 0.46
CYP1A2 P05177 1/20 0.46
HSP90AA1 P07900 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
GAA P10253 2/20 0.45
KDM4E B2RXH2 2/20 0.45
ABL1 P00519 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1515716 0.86 ALDH1A1 (0.53) ALDH1A1KMT2ALMNASMN1; SMN2MAPT
SCHEMBL17152701 0.85 MEN1 (0.49) ALDH1A1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL29641926 0.85 MEN1 (0.49) ALDH1A1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL5033639 0.84 ALDH1A1 (0.58) ALDH1A1LMNASMN1; SMN2MAPTTSHR
SCHEMBL11469172 0.84 ALDH1A1 (0.58) ALDH1A1LMNASMN1; SMN2MAPTTSHR
SCHEMBL16709897 0.82 KMT2A (0.47) ALDH1A1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL17142154 0.82 KMT2A (0.47) ALDH1A1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL17142153 0.82 KMT2A (0.47) ALDH1A1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL7458070 0.81 KDM4E (0.53) ALDH1A1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL7458061 0.81 KDM4E (0.53) ALDH1A1MEN1KMT2ALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023192989-A2 PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS AZKARRA THERAPEUTICS, INC. (US) 2023-10-05 WO disclosed
WO-2023192989-A2 PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS AZKARRA THERAPEUTICS, INC. (US) 2023-10-05 WO disclosed
EP-3325465-B1 PESTICIDALLY ACTIVE PYRAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2022-05-18 EP disclosed
EP-3325465-B1 PESTICIDALLY ACTIVE PYRAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2022-05-18 EP disclosed
US-11091501-B2 Heterocyclic compounds as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2021-08-17 US disclosed
US-20200270240-A1 BENZOTHIAZOLE AND PYRIDOTHIAZOLE COMPOUNDS AS SUMO ACTIVATORS ICAHN SCHOOL MED MOUNT SINAI (US) 2020-08-27 US disclosed
US-20200270240-A1 BENZOTHIAZOLE AND PYRIDOTHIAZOLE COMPOUNDS AS SUMO ACTIVATORS ICAHN SCHOOL MED MOUNT SINAI (US) 2020-08-27 US disclosed
CN-107428720-B Substituted aminotriazoles as inhibitors of acid mammalian chitinase 昂科艾伦迪治疗法股份公司 2020-06-30 CN disclosed
EP-3654975-A1 BENZOTHIAZOLE AND PYRIDOTHIAZOLE COMPOUNDS AS SUMO ACTIVATORS Icahn School of Medicine at Mount Sinai (US) 2020-05-27 EP disclosed
EP-3233832-B1 SUBSTITUTED AMINO TRIAZOLES USEFUL AS ACIDIC MAMMALIAN CHITINASE INHIBITORS ONCOARENDI THERAPEUTICS SA (PL) 2019-11-20 EP disclosed
WO-2015067647-A1 SUBSTITUTED BENZAMIDES FOR THE TREATMENT OF ARTHROPODS BAYER CROPSCIENCE AG (DE) 2015-05-14 WO disclosed
WO-2015067647-A1 SUBSTITUTED BENZAMIDES FOR THE TREATMENT OF ARTHROPODS BAYER CROPSCIENCE AG (DE) 2015-05-14 WO disclosed
WO-2015067646-A1 SUBSTITUTED BENZAMIDES FOR TREATING ARTHROPODES BAYER CROPSCIENCE AG (DE) 2015-05-14 WO disclosed
WO-2015067646-A1 SUBSTITUTED BENZAMIDES FOR TREATING ARTHROPODES BAYER CROPSCIENCE AG (DE) 2015-05-14 WO disclosed
US-20150080364-A1 CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME ABIDE THERAPEUTICS, INC. (US) 2015-03-19 US disclosed
US-20140073651-A1 BENZAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2014-03-13 US disclosed
EP-2678317-A1 BENZAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2014-01-01 EP disclosed
WO-2012114268-A1 BENZAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2012-08-30 WO disclosed
EP-1996590-A1 SPIROINDOLINONE DERIVATIVES F. Hoffmann-la Roche AG (CH) 2008-12-03 EP disclosed
WO-2007104664-A1 SPIROINDOLINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11091501-B2 Heterocyclic compounds as RSV inhibitors SIRT1, FURIN, SIRT5 ALDH1A1 721/4885MEN1 2857/4885KMT2A 2100/4885
US-20200270240-A1 BENZOTHIAZOLE AND PYRIDOTHIAZOLE COMPOUNDS AS SUMO ACTIVATORS SUMO2, ATP2A2, ATP2A1 ALDH1A1 3082/4885MEN1 4225/4885KMT2A 1387/4885
US-20140073651-A1 BENZAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS P2RX3, P2RX7, P2RX1 ALDH1A1 1255/4885MEN1 3603/4885KMT2A 2816/4885
US-20150080364-A1 CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME CPS1, FABP4, VHL ALDH1A1 2586/4885MEN1 758/4885KMT2A 301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.